Cronos Quarterly..... Saving the best for last.Cann creeping...

Cronos Quarterly..... Saving the best for last.
Cann creeping back to .40c on the back of that.
1.2 Million in receipts and over 5 million in cash left, and a bit of debt.
Cronos Australia strap yourself in.
I'm sorry sentiment is now Buy.


ASX ANNOUNCEMENT28 April 2022March 2022 Quarterly Activities Report and Appendix 4C

• Mildura facility achieves practical completion • ODC permit granted for commercial cultivation at Mildura • Sales revenue up 334% on prior corresponding period• Significant subsequent events, including Exclusive option evaluation agreement signed with GSKo Satipharm Advanced CBD product gets green light from UK Food Standards Agencyo New working capital banking facility and revised terms for existing facility28 April 2022 – Cann Group Limited (ASX: CAN) (Cann or the Company) is pleased to provide its March 2022 Quarterly Activities Report and Appendix 4C. Financials Net cash outflows from operating activities for the quarter ending 31 March 2022 were $4.188million. Key cashflow items for the quarter were:• Cann collected $1.290 million in receipts from customers.• Cann received $1.667 million in GST receipts with a further $0.706 million to be to be received in April 2022.• Staff and administration costs were in line with expectations and consistent with the prior quarter. • Payments of $0.10 million were made to directors (being related parties) by way of salary payments.• Research and development expenses of $0.391 million were incurred during the quarter as the Company continued with its research and development program. • Cashflow from investing activities included $5.844 million in expenditure associated with the construction and development of Cann’s new production facility near Mildura. An amount of $4.744 million was drawn down from the Company’s NAB facility for this development.Sales and productionUnaudited sales revenue for the quarter ended 31 March 2022 was $1.270 million representing a 334% increase to the prior corresponding period. A number of factors have contributed to this revenue growth including increased sales of extracted oil formulations to existing and new customers, new sales of dried flower products released from our newly GMP licensed Southern